Published on
The $200,000 award will fund research to develop a novel therapeutic that ignites the immune system and could act as a stand-alone treatment, as well as boost the effectiveness of existing immunotherapies.
Published on
CHOP has opened a phase 1 trial using CAR T for tough acute myeloid leukemia, hoping to replicate the therapy’s success for acute lymphoblastic leukemia.
Published on
CHOP’s Cancer Center helps families manage the extreme emotions elicited by a child’s cancer diagnosis through its world-class, comprehensive, innovative psychosocial services.
Published on
An alternative, humanized CD19 CAR T product for first relapse of pediatric ALL is being evaluated in a clinical trial at Children's Hospital of Philadelphia.
Published on
CHOP researchers analyze how some cancer cells resist a groundbreaking cellular therapy, and have found clues to overcoming that resistance.
Published on
The $220,000 award will be directed to a Phase I clinical trial that will investigate the effectiveness of CAR T-cell therapy to treat AML.
Published on
A bone marrow transplant saved Kaleo’s life. Today, he’s a dancing machine. His success story is an example of CHOP’s expertise in the field of cellular therapy.
Published on
Thanks to a recent initiative at CHOP, patients newly diagnosed with B-cell and T-cell ALL, and lymphoblastic lymphoma, now go home on average 9 days after diagnosis — that's 3 weeks sooner than previous stays.
Published on
With the majority of Hodgkin lymphoma patients surviving their disease, the focus has turned to minimizing the long-term effects of treatment while maintaining excellent cure rates.
Published on
Charles Phillips, MD, a CHOP fellow, recounts his experience caring for a cancer patient and the many firsts it brought to the both of them.